BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-1146@pharmaconomics
DTSTAMP:20260707T015956Z
DTSTART;VALUE=DATE:20260510
DTEND;VALUE=DATE:20260511
SUMMARY:ARGX PDUFA — VYVGART
DESCRIPTION:The FDA's approval decision on VYVGART for generalized myasthenia gravis (gMG) is due May 10\, 2026. A green light opens the market\; a complete response letter (CRL) usually sinks the stock.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1697862/000110465926045083/tm2612048d1_ex99-1.htm\n\nTrack it: https://pharmaconomics.com/e/1146
URL:https://pharmaconomics.com/e/1146
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:ARGX catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR